Jessica Merrill

<p>An overall survival benefit for patients in TALAPRO-2 could pave the way for a broader label for the combination in metastatic prostate cancer. </p>

<p>Deal Snapshot: Boehringer Ingelheim will work to develop a cyclin inhibitor that can stop cancer cell growth, using Circle’s macrocycle platform. </p>

<p>The IL-23 inhibitor was approved by the US FDA for ulcerative colitis, joining AbbVie’s Skyrizi and Lilly’s Omvoh. </p>

<p>The Roivant-owned company announced positive Phase II data for batoclimab in Graves’ disease and plans to advance next-generation IMVT-1402 into Phase III. </p>

<p><span>The company laid out a growth strategy to investors centered on three business units, $4bn in revenue by 2027 and $500m in cost savings.&nbsp;</span></p>

<p>The US presidential election in November could mean IRA expansion from a Biden win, but a Trump victory also brings uncertainty. </p>

<span>Industry leaders and experts at the Financial Times Pharma and Biotech Summit said the US relationship with China adds pressing risk to pharma.</span>

<p>The company said it has the financing to move forward with a Phase III program for zerlasiran in patients with high lipoprotein(a) <span></span>at high risk of atherosclerotic cardiovascular disease. </p>

<p>CEO Joaquin Duato said J&amp;J is agnostic on size when it comes to business development but has generally found more value creation in earlier-stage deals. </p>

<span>An uptick in deals and an improving macro-economic outlook laid the groundwork for a rosier sentiment across much of the industry at the annual health care conference.</span>

<p>New York has its eye on becoming a premier biotech hub and is investing heavily in life sciences. Experts weighed in on the positives and drawbacks of the city for biotechs at a new innovation campus called Cure.</p>

<p>Multiple gene therapies have been approved in the last couple of years, but market access and reimbursement for gene therapies remain challenging – a key theme of the Cell &amp; Gene Meeting on the Mesa. </p>

<p>Amgen’s Amjevita, the first biosimilar of Humira to launch in the US, hasn’t made headway into the US market, according to Samsung Bioepis’ quarterly market report on the US biosimilars market. <span></span></p>